LUMABS BV has setup operations and it’s Assay Development Lab at the Hid/Sanquin, in Amsterdam in 2023. We are currently developing diverse assays in collaboration with other diagnostic manufacturers, while implementing a full complaint ISO 13485 laboratory/operations. LUMABS BV is developing its own range of immunoassays using its fast, quantitative bioluminescence immunoassay technology platform, RAPPID, with a focus on SEPSIS and other inflamation markers as well as Therapeutical Drug Monitoring (TDM) POC solutions for measuresing the blood concentration of drugs for immune mediated inflammatory disease and TDM for Antibiotic dosing through model-informed precision dosing (MIPD). LUMABS is looking for co-development opportunities with diagnostic companies that have already heterogeneous immunoassays using technology platforms such as ELISA/CLIA/TR-IFA, therefore available pairs of antibodies that can be used with our new bioluminescence-based sensors and coverted to homogeneous immunoassays with the same or higher sensitivity but always with TTR <30min.
Menu
